Transcat TRNS 深 沪
已收盘 12-19 16:00:00 美东时间
59.55
-0.740
-1.23%
华盛通- 最 高60.87
- 今 开60.25
- 成交量 16.25万股
- 最 低 59.00
- 昨 收 60.29
- 总市值 5.56亿
- 52周最高 111.29
- 市盈率 静 37.97
- 换手率 1.74%
- 52周最低 50.23
- 委 比 79.25%
- 总股本 932.84万
- 历史最高 147.115
- 量 比 0.92
- 振 幅 3.10%
- 历史最低 4.97
- 每 手 1
- 风险率 12.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Edwards Lifesciences 2026 EPS guidance range includes consensus
Edwards Lifesciences (EW) newly projected 2026 adjusted EPS guidance of $2.80-$2.95 includes to consensus figure of $2.86. The maker of products to treat advanced cardiovascular diseases also sees con...
12-04 23:07
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
Anteris Technologies Global Corp. announced 30-day clinical outcomes for the DurAVR® THV in 100 severe aortic stenosis patients with small aortic annuli. The device showed favorable hemodynamic performance, including low pressure gradients, reduced prosthesis-patient mismatch (PPM), and no moderate or severe paravalvular leaks. With a 97% freedom from moderate or severe PPM and 100% technical success rate in the last 50 implants, the DurAVR® THV ...
11-17 11:00
Anteris Announces Results for the Third Quarter of 2025
Anteris reported Q3 2025 financial results, highlighting FDA and European approvals for the PARADIGM Trial, patient recruitment progress, operational readiness enhancements, and $59.3 million net cash outflow. Key focus areas included regulatory advancement, clinical trial preparation, and manufacturing scale-up.
11-12 22:52
Transcat Q2 Adj. EPS $0.44 Misses $0.51 Estimate, Sales $82.300M Beat $79.512M Estimate
Transcat (NASDAQ:TRNS) reported quarterly earnings of $0.44 per share which missed the analyst consensus estimate of $0.51 by 12.87 percent. This is a 15.38 percent decrease over earnings of $0.52 per share from the same
11-04 04:51
Anteris Receives FDA Approval To Initiate PARADIGM, Global IDE Clinical Trial Designed To Evaluate DurAVR THV In Patients With Severe Calcific Aortic Stenosis And To Support Future PMA Submission
PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devicesMINNEAPOLIS and BRISBANE, Australia,
11-03 20:24
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
An Overview of Transcat's Earnings
Transcat (NASDAQ:TRNS) is gearing up to announce its quarterly earnings on Mond...
11-01 03:02
华尔街顶级分析师最新评级报告：联合健康遭下调
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总于此。以下是由 The Fly 整理的今日投资者需重点关注的评级信息。 五大评级上调案例 思佳讯...
10-29 22:12
Autonomix Medical To Present At TCT 2025 Conference Showcasing Initial Results From Its First-in-Human Study On Transvascular Nerve-Targeted Therapy To Reduce Pancreatic Cancer Pain
Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium
10-24 21:05
Anteris Technologies Receives Danish Regulatory Clearance To Launch Global PARADIGM Trial For DurAVR Heart Valve
Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR))) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore
10-15 21:21
